ID

42334

Description

Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT01316224

Lien

https://clinicaltrials.gov/show/NCT01316224

Mots-clés

  1. 15/06/2021 15/06/2021 -
  2. 15/06/2021 15/06/2021 -
Détendeur de droits

AbbVie (prior sponsor, Abbott)

Téléchargé le

15 juin 2021

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Psoriatic Arthritis in Psoriasis NCT01316224

Eligibility Psoriatic Arthritis in Psoriasis NCT01316224

Inclusion Criteria
participant has a documented clinical diagnosis of psoriasis, as determined by participant interview of his/her medical history and confirmation of diagnosis through physical examination by the investigator
participant has indication of psoriasis systemic therapy
if female, participant is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control: condoms, sponge, foams, jellies, diaphragm or intrauterine device (iud)
contraceptives (oral or parenteral) for three months (90 days) prior to study drug administration
a vasectomized partner
total abstinence from sexual intercourse
able and willing to give written informed consent and comply with the requirements of the study protocol
Exclusion Criteria
participants who have active infections
participants enrolled in another study or clinical trial
any condition that according to the criteria of the participating investigator represents an obstacle for study conduction and/or participants to an unacceptable risk
history of active tuberculosis (tb), histoplasmosis or listeriosis

Similar models

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial